RAM
HRTX icon

Redmond Asset Management’s Heron Therapeutics HRTX Stock Holding History

Redmond Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-65,136
Closed -$275K – 173
2022
Q3 		$275K Sell
65,136
-253
-0.4% -$990 0.1% 150
2022
Q2 		$182K Sell
65,389
-4,370
-6% -$17.5K 0.07% 175
2022
Q1 		$399K Buy
69,759
+23,736
+52% +$174K 0.12% 160
2021
Q4 		$420K Sell
46,023
-5,224
-10% -$53.3K 0.12% 163
2021
Q3 		$548K Hold
51,247
– – 0.17% 146
2021
Q2 		$795K Sell
51,247
-23
-0% -$366 0.23% 131
2021
Q1 		$831K Buy
51,270
+155
+0.3% +$2.76K 0.26% 124
2020
Q4 		$1.08M Buy
51,115
+4,625
+10% +$80.4K 0.38% 89
2020
Q3 		$689K Buy
46,490
+172
+0.4% +$2.68K 0.29% 112
2020
Q2 		$681K Sell
46,318
-217
-0.5% -$3.56K 0.28% 104
2020
Q1 		$546K Buy
46,535
+689
+2% +$13K 0.27% 107
2019
Q4 		$1.08M Buy
45,846
+211
+0.5% +$4.67K 0.46% 73
2019
Q3 		$844K Buy
45,635
+68
+0.1% +$1.25K 0.37% 87
2019
Q2 		$847K Buy
45,567
+436
+1% +$8.71K 0.36% 94
2019
Q1 		$1.1M Buy
+45,131
New +$1.18M 0.48% 76

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Redmond Asset Management's HRTX Position: Q4 2022 in Review

Redmond Asset Management sold out of Heron Therapeutics (HRTX) in Q4 2022, closing a stake of 65,136 shares — an estimated $275K sold.

Redmond Asset Management first reported a position in HRTX in Q1 2019 and held it in 15 quarters. The position peaked at $1.1M in Q1 2019. 176 funds tracked by Wall St. Rank hold HRTX as of Q4 2022.

  • Redmond Asset Management reported no remaining Heron Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Redmond Asset Management sold 65,136 Heron Therapeutics shares in Q4 2022, an estimated $275K.
  • Redmond Asset Management first reported a position in Heron Therapeutics in Q1 2019 and held it in 15 quarters.
  • Redmond Asset Management's Heron Therapeutics position peaked at $1.1M in Q1 2019.
  • 176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2022.

Based on Redmond Asset Management's 13F filing for Q4 2022, filed 6 Feb 2023.